A Phase 1B Study of N-803 Combined With the Broadly Neutralizing Antibodies VRC07-523LS and PGT121 Plus or Minus haNK Cells for Reduction of HIV Reservoirs
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio; PGT 121; TMB-380
- Indications HIV-1 infections
- Focus Adverse reactions
- 24 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment due to contact issues
- 18 Nov 2019 Planned initiation date changed from 1 Nov 2019 to 1 Jan 2020.
- 06 Nov 2019 New trial record